Innate Type-2 Cytokines: From Immune Regulation to Therapeutic Targets

키워드

참고문헌 (105)

1. Janeway CA Jr, "Innate immune recognition", Annu Rev Immunol, 20, pp.197~216 (2002)
2. Wynn TA, "Type 2 cytokines : mechanisms and therapeutic strategies", Nat Rev Immunol, 15, pp.271~282 (2015)
3. Licona-Limón P, "TH2, allergy and group 2 innate lymphoid cells", Nat Immunol, 14, pp.536~542 (2013)
4. Akdis CA, "Type 2 immunity in the skin and lungs", Allergy, 75, pp.1582~1605 (2020)
5. Ham J, "Targeting the epithelium-derived innate cytokines : from bench to bedside", Immune Netw, 22, pp.e11~ (2022)
6. McGeachy MJ, "The IL-17 family of cytokines in health and disease", Immunity, 50, pp.892~906 (2019)
7. Kouzaki H, "Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells", Am J Respir Cell Mol Biol, 49, pp.741~750 (2013)
8. Min HK, "Interleukin(IL)-25 suppresses IL-22-induced osteoclastogenesis in rheumatoid arthritis via STAT3 and p38 MAPK", IκBα pathway, 2020, pp.22, 222~
9. Sonobe Y, "Interleukin-25 expressed by brain capillary endothelial cells maintains blood-brain barrier function in a protein kinase Cepsilon-dependent manner", J Biol Chem, 284, pp.31834~31842 (2009)
10. Goswami S, "Divergent functions for airway epithelial matrix metalloproteinase 7 and retinoic acid in experimental asthma", Nat Immunol, 10, pp.496~503 (2009)
11. Hurst SD, "New IL-17 family members promote Th1 or Th2 responses in the lung : in vivo function of the novel cytokine IL-25", J Immunol, 169, pp.443~453 (2002)
12. Fort MM, "IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo", Immunity, 15, pp.985~995 (2001)
13. Terashima A, "A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity", J Exp Med, 205, pp.2727~2733 (2008)
14. Stock P, "Induction of airway hyperreactivity by IL-25 is dependent on a subset of invariant NKT cells expressing IL-17RB", J Immunol, 182, pp.5116~5122 (2009)
15. Owyang AM, "Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract", J Exp Med, 203, pp.843~849 (2006)
16. Drake LY, "IL-33 : biological properties, functions, and roles in airway disease", Immunol Rev, 278, pp.173~184 (2017)
17. Kakkar R, "The IL-33", ST2 pathway : therapeutic target and novel biomarker, 2008, pp.7, 827~840
18. Cayrol C, "Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33", Nat Immunol, 19, pp.375~385 (2018)
19. Lefrançais E, "IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G", Proc Natl Acad Sci U S A, 109, pp.1673~1678 (2012)
20. Roy A, "Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33(IL-33)and limits danger-induced inflammation", J Biol Chem, 289, pp.237~250 (2014)
21. Cayrol C, "Interleukin-33(IL-33) : a nuclear cytokine from the IL-1 family", Immunol Rev, 281, pp.154~168 (2018)
22. Cherry WB, "A novel IL-1 family cytokine, IL-33, potently activates human eosinophils", J Allergy Clin Immunol, 121, pp.1484~1490 (2008)
23. Sehmi R, "Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma", Clin Exp Allergy, 46, pp.793~802 (2016)
24. Tran VG, "IL-33 priming enhances peritoneal macrophage activity in response to candida albicans", Immune Netw, 14, pp.201~206 (2014)
25. Kearley J, "Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1", ST2-IL-33 pathway, 2009, pp.179, 772~781
26. Yin H, "Adenovirus-mediated delivery of soluble ST2 attenuates ovalbumin-induced allergic asthma in mice", Clin Exp Immunol, 170, pp.1~9 (2012)
27. Smith DE, "IL-33 : a tissue derived cytokine pathway involved in allergic inflammation and asthma", Clin Exp Allergy, 40, pp.200~208 (2010)
28. Corren J, "TSLP : from allergy to cancer", Nat Immunol, 20, pp.1603~1609 (2019)
29. Fornasa G, "Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin", J Allergy Clin Immunol, 136, pp.413~422 (2015)
30. Pattarini L, "TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand", J Exp Med, 214, pp.1529~1546 (2017)
31. Ahn S, "GM-CSF and IL-4 produced by NKT cells inversely regulate IL-1β production by macrophages", Immunol Lett, 182, pp.50~56 (2017)
32. Brennan PJ, "Invariant natural killer T cells : an innate activation scheme linked to diverse effector functions", Nat Rev Immunol, 13, pp.101~117 (2013)
33. Michel ML, "Critical role of ROR-γt in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation", Proc Natl Acad Sci U S A, 105, pp.19845~19850 (2008)
34. Gumperz JE, "Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining", J Exp Med, 195, pp.625~636 (2002)
35. Burdin N, "Selective ability of mouse CD1 to present glycolipids : alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes", J Immunol, 161, pp.3271~3281 (1998)
36. Bendelac A, "The biology of NKT cells", Annu Rev Immunol, 25, pp.297~336 (2007)
37. Georgiev H, "Distinct gene expression patterns correlate with developmental and functional traits of iNKT subsets", Nat Commun, 7, pp.13116~ (2016)
38. Lee YJ, "Lineage-specific effector signatures of invariant NKT cells are shared amongst γδ T, innate lymphoid, and Th cells", J Immunol, 197, pp.1460~1470 (2016)
39. Lee YJ, "Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells", Nat Immunol, 14, pp.1146~1154 (2013)
40. Baranek T, "High dimensional single-cell analysis reveals iNKT cell developmental trajectories and effector fate decision", Cell Reports, 32, pp.108116~ (2020)
41. Berga-Bolaños R, "β-Catenin is required for the differentiation of iNKT2 and iNKT17 cells that augment IL-25-dependent lung inflammation", BMC Immunol, 16, pp.62~ (2015)
42. Shin SB, "ILC-you in the thymus : a fresh look at innate lymphoid cell development", Front Immunol, 12, pp.681110~ (2021)
43. Vivier E, "Innate lymphoid cells : 10 years on", Cell, 174, pp.1054~1066 (2018)
44. Zhang J, "T-bet and Eomes govern differentiation and function of mouse and human NK cells and ILC1", Eur J Immunol, 48, pp.738~750 (2018)
45. Chiossone L, "Natural killer cells and other innate lymphoid cells in cancer", Nat Rev Immunol, 18, pp.671~688 (2018)
46. Kortekaas Krohn I, "Emerging roles of innate lymphoid cells in inflammatory diseases : clinical implications", Allergy, 73, pp.837~850 (2018)
47. Woo Y, "The roles of innate lymphoid cells in the development of asthma", Immune Netw, 14, pp.171~181 (2014)
48. Meininger I, "Tissue-specific features of innate lymphoid cells", Trends Immunol, 41, pp.902~917 (2020)
49. Smith SG, "Increased numbers of activated group 2 innate lymphoid cells in the airways of patients with severe asthma and persistent airway eosinophilia", J Allergy Clin Immunol, 137, pp.75~86 (2016)
50. Sugita K, "Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients", J Allergy Clin Immunol, 141, pp.300~310 (2018)
51. Wallrapp A, "Type 2 innate lymphoid cells in the induction and resolution of tissue inflammation", Immunol Rev, 286, pp.53~73 (2018)
52. Rothenberg ME, "The eosinophil", Annu Rev Immunol, 24, pp.147~174 (2006)
53. Karasuyama H, "Nonredundant roles of basophils in immunity", Annu Rev Immunol, 29, pp.45~69 (2011)
54. Voehringer D, "Protective and pathological roles of mast cells and basophils", Nat Rev Immunol, 13, pp.362~375 (2013)
55. Xue L, "Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells", J Allergy Clin Immunol, 133, pp.1184~1194 (2014)
56. Karasuyama H, "How do basophils contribute to Th2 cell differentiation and allergic responses?", Int Immunol, 30, pp.391~396 (2018)
57. De Filippo K, "Mast cell and macrophage chemokines CXCL1", CXCL2 control the early stage of neutrophil recruitment during tissue inflammation, 2013, pp.121, 4930~4937
58. Robinson D, "Revisiting type 2-high and type 2-low airway inflammation in asthma : current knowledge and therapeutic implications", Clin Exp Allergy, 47, pp.161~175 (2017)
59. Fukuda T, "Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma", Am J Respir Cell Mol Biol, 14, pp.84~94 (1996)
60. Doran E, "Interleukin-13 in asthma and other eosinophilic disorders", Front Med(Lausanne), 4, pp.139~ (2017)
61. Medzhitov R, "Disease tolerance as a defense strategy", Science, 335, pp.936~941 (2012)
62. Artis D, "The biology of innate lymphoid cells", Nature, 517, pp.293~301 (2015)
63. Acharya KR, "Eosinophil granule proteins : form and function", J Biol Chem, 289, pp.17406~17415 (2014)
64. Neill DR, "Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity", Nature, 464, pp.1367~1370 (2010)
65. Price AE, "Systemically dispersed innate IL-13-expressing cells in type 2 immunity", Proc Natl Acad Sci U S A, 107, pp.11489~11494 (2010)
66. Mallevaey T, "Activation of invariant NKT cells by the helminth parasite schistosoma mansoni", J Immunol, 176, pp.2476~2485 (2006)
67. Pawankar R, "Allergic diseases and asthma : a major global health concern", Curr Opin Allergy Clin Immunol, 12, pp.39~41 (2012)
68. Siracusa MC, "Basophils and allergic inflammation", J Allergy Clin Immunol, 132, pp.789~801 (2013)
69. Kim HY, "The many paths to asthma : phenotype shaped by innate and adaptive immunity", Nat Immunol, 11, pp.577~584 (2010)
70. Aneas I, "Asthma-associated genetic variants induce IL33 differential expression through an enhancer-blocking regulatory region", Nat Commun, 12, pp.6115~ (2021)
71. Kim J, "Innate immune crosstalk in asthmatic airways : innate lymphoid cells coordinate polarization of lung macrophages", J Allergy Clin Immunol, 143, pp.1769~1782 (2019)
72. Bourgeois E, "The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production", Eur J Immunol, 39, pp.1046~1055 (2009)
73. Smithgall MD, "IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells", Int Immunol, 20, pp.1019~1030 (2008)
74. Gieseck RL 3rd, "Type 2 immunity in tissue repair and fibrosis", Nat Rev Immunol, 18, pp.62~76 (2018)
75. Hinz B, "Recent developments in myofibroblast biology : paradigms for connective tissue remodeling", Am J Pathol, 180, pp.1340~1355 (2012)
76. Wynn TA, "Integrating mechanisms of pulmonary fibrosis", J Exp Med, 208, pp.1339~1350 (2011)
77. Fichtner-Feigl S, "Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis", Mucosal Immunol, 1(Suppl 1), pp.S24~S27 (2008)
78. Yanagi S, "Breakdown of epithelial barrier integrity and overdrive activation of alveolar epithelial cells in the pathogenesis of acute respiratory distress syndrome and lung fibrosis", BioMed Res Int, 2015, pp.573210~ (2015)
79. Baurakiades E, "The roles of ADAM33, ADAM28, IL-13 and IL-4 in the development of lung injuries in children with lethal non-pandemic acute infectious pneumonia", J Clin Virol, 61, pp.585~589 (2014)
80. Heitmann L, "The IL-13", IL-4Rα axis is involved in tuberculosis-associated pathology, 2014, pp.234, 338~350
81. Pellicoro A, "Liver fibrosis and repair : immune regulation of wound healing in a solid organ", Nat Rev Immunol, 14, pp.181~194 (2014)
82. Li J, "Th2 signals induce epithelial injury in mice and are compatible with the biliary atresia phenotype", J Clin Invest, 121, pp.4244~4256 (2011)
83. Wang W, "Control of brown and beige fat development", Nat Rev Mol Cell Biol, 17, pp.691~702 (2016)
84. Mahlakõiv T, "Stromal cells maintain immune cell homeostasis in adipose tissue via production of interleukin-33", Sci Immunol, 4, pp.eaax0416~ (2019)
85. Odegaard JI, "Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance", Nature, 447, pp.1116~1120 (2007)
86. Molofsky AB, "Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages", J Exp Med, 210, pp.535~549 (2013)
87. Lynch L, "Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production", Immunity, 37, pp.574~587 (2012)
88. Hams E, "Cutting edge : IL-25 elicits innate lymphoid type 2 and type II NKT cells that regulate obesity in mice", J Immunol, 191, pp.5349~5353 (2013)
89. Camelo A, "Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13", J Gastroenterol, 47, pp.1198~1211 (2012)
90. O’Byrne PM, "Development of an inhaled anti-TSLP therapy for asthma", Pulm Pharmacol Ther, 78, pp.102184~ (2023)
91. Karo-Atar D, "Therapeutic targeting of the interleukin-4", interleukin-13 signaling pathway : in allergy and beyond, 2018, pp.32, 201~220
92. Corren J, "Lebrikizumab treatment in adults with asthma", N Engl J Med, 365, pp.1088~1098 (2011)
93. Panettieri RA Jr, "Tralokinumab for severe, uncontrolled asthma(STRATOS 1 and STRATOS 2) : two randomised, double-blind, placebo-controlled, phase 3 clinical trials", Lancet Respir Med, 6, pp.511~525 (2018)
94. Paul WE, "How are T(H)2-type immune responses initiated and amplified?", Nat Rev Immunol, 10, pp.225~235 (2010)
95. Busse WW, "Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma : 1-year results from the BORA phase 3 extension trial", Lancet Respir Med, 7, pp.46~59 (2019)
96. Weinstein SF, "Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma", J Allergy Clin Immunol, 142, pp.171~177 (2018)
97. Bachert C, "Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps(LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials", Lancet, 394, pp.1638~1650 (2019)
98. Simpson EL, "Two phase 3 trials of dupilumab versus placebo in atopic dermatitis", N Engl J Med, 375, pp.2335~2348 (2016)
99. Fallon PG, "Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13 : IL-13 is a profibrotic agent", J Immunol, 164, pp.2585~2591 (2000)
100. Mentink-Kane MM, "IL-13 receptor alpha 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis", Proc Natl Acad Sci U S A, 101, pp.586~590 (2004)
101. Rosenberg HF, "Eosinophils : changing perspectives in health and disease", Nat Rev Immunol, 13, pp.9~22 (2013)
102. Nair P, "Oral glucocorticoid-sparing effect of benralizumab in severe asthma", N Engl J Med, 376, pp.2448~2458 (2017)
103. Chupp GL, "Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma(MUSCA) : a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial", Lancet Respir Med, 5, pp.390~400 (2017)
104. Reiman RM, "Interleukin-5(IL-5)augments the progression of liver fibrosis by regulating IL-13 activity", Infect Immun, 74, pp.1471~1479 (2006)
105. Swartz JM, "Schistosoma mansoni infection in eosinophil lineage-ablated mice", Blood, 108, pp.2420~2427 (2006)

관련 논문AI추천